The editorial TLDR.
ApoB — apolipoprotein B — is the protein that sits on the outside of every "bad cholesterol" particle in the bloodstream. Each of those particles carries exactly one ApoB molecule, which means a single ApoB number is effectively a direct count of the lipoprotein particles most associated with atherosclerosis. Modern cardiology has been moving toward ApoB for over a decade as a more accurate marker than LDL cholesterol — particularly in women, in people with metabolic syndrome or PCOS, and in anyone with a normal-looking standard panel but persistent cardiovascular risk on the family-history side.
Most U.S. labs report ApoB in milligrams per deciliter (mg/dL). For educational reference, many clinicians treat under 90 mg/dL as a reasonable target for healthy adults without established cardiovascular disease, and tighter targets (under 80, sometimes under 60) for higher-risk patients. The threshold is not the diagnosis — it's a continuous number, with risk rising as the count climbs. Below about 80 mg/dL is the band many preventive cardiologists describe as comfortable.
For U.S. women, ApoB is the marker that often gets ordered too late — sometimes a decade after it could have changed the picture. Cardiovascular disease is the leading cause of death in American women, and the patterns that drive it (insulin resistance, perimenopausal lipid shifts, family history) can show up on an ApoB panel years before they show up on standard cholesterol or on imaging. As always, what you do about it is a conversation worth having with a qualified healthcare provider.
What ApoB actually is.
Cholesterol can't move through the bloodstream on its own — it isn't soluble in water. To travel, it packages itself into spherical particles called lipoproteins, with fats on the inside and proteins on the outside. The two major families of lipoprotein particles relevant to atherosclerosis are the LDL family (low-density lipoproteins) and a few of its cousins: VLDL, IDL, chylomicron remnants, and lipoprotein(a). All of these "atherogenic" particles carry a structural protein called apolipoprotein B-100 — ApoB for short — and each particle carries exactly one.
That last detail is the entire point of the test. If you can count ApoB, you can count every atherogenic particle in circulation. You don't need to estimate it from the cholesterol content of those particles, which is what a standard LDL cholesterol number does. The LDL-C value is a measurement of the cargo (cholesterol) inside the particles, not the particles themselves. Two women with identical LDL-C readings can have meaningfully different particle counts — one with a smaller number of large cholesterol-rich particles, another with a larger number of smaller cholesterol-poor particles. The second pattern carries more cardiovascular risk, even when LDL-C looks the same.
"LDL-C is the cargo inside the trucks. ApoB is the number of trucks. The number of trucks is what hits the wall."
Modern cardiology has been moving toward ApoB on the basis of large prospective studies — INTERHEART, EPIC-Norfolk, AMORIS — showing that ApoB outperforms LDL-C as a predictor of cardiovascular events, particularly in people with insulin resistance, metabolic syndrome, type 2 diabetes, or elevated triglycerides. Major guidelines from the European Society of Cardiology now include ApoB as a recommended marker, and U.S. preventive cardiology practice has steadily followed. The American College of Cardiology's 2018 cholesterol guidelines recognize ApoB as a useful additional marker, particularly when standard lipids underestimate risk.
The standard test is a venous blood draw, run as a fasting or non-fasting immunoassay, and reported in mg/dL. The result is stable across cycle days, doesn't require any unusual prep beyond the fasting question, and is typically inexpensive to add to an existing lipid panel.
Why ApoB matters for women.
Cardiovascular disease is the leading cause of death in U.S. women — far ahead of all cancers combined, including breast cancer. The patterns that drive women's cardiovascular risk are not identical to men's, and ApoB is one of the markers that captures the difference better than standard cholesterol does.
The perimenopausal lipid shift. Estrogen has a protective effect on the lipid profile through the reproductive years. As estrogen falls in perimenopause and menopause, LDL particle number tends to rise, triglycerides drift upward, and the average LDL particle size often shifts smaller. The result on a standard cholesterol panel can look subtle — LDL-C might creep up modestly — while ApoB rises more meaningfully. This is one of the windows where a single ApoB check gives a more honest read on what's happening than a standard panel.
PCOS and insulin resistance. Women with polycystic ovary syndrome or other insulin-resistant patterns frequently carry an atherogenic lipid profile that hides on a standard panel: normal-ish LDL-C, normal-ish total cholesterol, but elevated triglycerides, low HDL, and a higher count of small dense LDL particles. ApoB catches this pattern. Standard lipids often miss it until much later. The American Heart Association and the Endocrine Society both flag PCOS as a cardiovascular risk-modifying condition partly for this reason.
Family history of early cardiovascular disease. Familial patterns — early heart attacks in male relatives under 55, female relatives under 65, or familial hypercholesterolemia — are reasons to look beyond standard cholesterol earlier than the calendar might suggest. ApoB is one of the more useful markers for women who carry these family patterns and want a clearer baseline in their thirties or forties rather than their fifties.
Pregnancy-related conditions. A history of preeclampsia, gestational diabetes, or hypertension in pregnancy is increasingly recognized as a cardiovascular risk modifier in women. Many preventive cardiologists factor these into the decision to add ApoB to a routine workup, even when standard lipids look unremarkable.
The "too early" problem. A common pattern: a 40-year-old woman with a normal cholesterol panel is told her cardiovascular risk is low. Fifteen years later, in perimenopause, her LDL-C rises and she begins a statin conversation. ApoB at 40 might have shown an underlying pattern that the standard panel missed — not because risk would have been acutely high at 40, but because it would have informed earlier, gentler lifestyle conversations rather than a more aggressive intervention later. Whether women should have access to ApoB earlier is one of the more reasonable critiques of current U.S. screening practice.
What the ranges generally mean.
Most U.S. labs report ApoB in milligrams per deciliter (mg/dL). The clinical convention is to discuss ApoB in bands rather than a single threshold; risk rises continuously as the number climbs.
ApoB educational reference, adult women
mg / dLIllustrative educational targets, not diagnostic thresholds. ApoB risk is continuous and varies by age, family history, lipoprotein(a), other lipids and overall context. Always discuss your specific result with a qualified healthcare provider.
What may drive ApoB low or high.
The patterns below come up most often when ApoB sits outside the comfortable zone — particularly in U.S. women.
What may drive ApoB elevated.
- Insulin resistance and metabolic syndrome. The classic driver of elevated ApoB in women, particularly with PCOS, central adiposity or fatty liver.
- Perimenopause and menopause. Estrogen decline shifts lipoprotein metabolism upward. A meaningful share of U.S. women see ApoB climb in their late forties and fifties.
- Familial hypercholesterolemia. A heritable pattern that elevates LDL particles from a young age. Often missed because it doesn't always present with dramatically elevated total cholesterol on a standard panel.
- Hypothyroidism. Low thyroid function slows LDL receptor activity in the liver, raising particle counts. ApoB often improves when thyroid is restored to comfortable range.
- Diet pattern. Diets very high in saturated fat (or refined carbohydrate, in insulin-resistant women) tend to raise ApoB. Dietary effects are real but modest — usually 10–20% changes, sometimes more.
- Sedentary patterns. Reduced physical activity is associated with higher ApoB independently of other factors.
- Alcohol and ultra-processed food. Both tend to push triglycerides and small dense LDL particles up.
- Certain medications. Long-term corticosteroids, certain anti-seizure medications, and some HIV medications can raise ApoB.
What may drive ApoB low.
- Naturally protective genetics. Some women carry variants that produce naturally low ApoB and very low lifetime cardiovascular risk.
- Statin or PCSK9 inhibitor therapy. By far the most common medication-related reason. These drugs reduce ApoB significantly.
- Hyperthyroidism. An overactive thyroid accelerates LDL clearance, dropping ApoB.
- Severe malnutrition or malabsorption. Including significant weight loss, untreated celiac disease, or major bariatric surgery.
- Severe liver disease. Reduced ApoB production. Often associated with other liver markers being abnormal.
Why women may benefit from ApoB earlier than they're offered it.
The conventional U.S. approach is to screen with a standard lipid panel (total cholesterol, LDL-C, HDL, triglycerides) and only add ApoB when the standard panel is borderline or risk factors accumulate. That works for many women — and misses a meaningful minority.
The pattern most often missed: a 30- or 40-year-old woman with PCOS, a family history of early heart disease, or a history of preeclampsia or gestational diabetes, whose standard cholesterol looks fine. Standard lipids underestimate her atherogenic particle count. ApoB tells the truer story — often a decade before standard markers shift enough to trigger conversation.
This isn't an argument for routine ApoB on every 30-year-old. It's an argument that the women most likely to be told their cardiovascular risk is low based on a standard panel are sometimes the women for whom ApoB matters most.
Questions worth asking your healthcare provider.
Conversation starters, not a script. These prompts help bring ApoB into a cardiovascular conversation that often defaults to LDL-C alone:
- Given my family history, PCOS, or pregnancy complications, can we add ApoB and lipoprotein(a) to my next lipid panel?
- What ApoB target would you aim for given my age, family history and current cardiovascular risk picture?
- If my ApoB looks borderline but my LDL-C is fine, how would you interpret that — and what would change next?
- Should we look at hsCRP alongside ApoB for a fuller cardiometabolic baseline?
- If I've had preeclampsia or gestational diabetes in pregnancy, how does that factor into your cardiovascular risk assessment?
- How often should we recheck, and what changes would prompt earlier follow-up?
Your provider will guide the conversation based on your full medical context. These prompts are designed to make sure ApoB doesn't get left out simply because it isn't on the default order set.
When to test, and how it's measured.
ApoB is a standard venous blood draw. It can be ordered alongside a regular lipid panel (most labs add it for a small additional fee) or as part of a more comprehensive cardiovascular panel that includes lipoprotein(a), hsCRP and fasting insulin or HbA1c.
Fasting versus non-fasting. ApoB is reasonably stable across fasting and non-fasting draws — more stable than triglycerides, which can swing meaningfully after a meal. Many modern lipid guidelines have moved toward non-fasting testing as the default for both convenience and accuracy. If your provider still asks for a fasting draw, that's fine — it just isn't strictly necessary for ApoB specifically.
Cycle day doesn't materially affect ApoB. If you're on hormonal contraception, hormone therapy, or recently started or stopped either, mention it on the requisition — exogenous estrogens can shift the lipid panel modestly. Pregnancy is a state where lipids and ApoB rise normally; testing during pregnancy isn't generally informative for long-term risk.
Direct-to-consumer at-home tests — Function Health, LetsGetChecked, Quest Direct and others — include ApoB in their broader cardiovascular and cardiometabolic panels. They're useful for a baseline, particularly if your regular physical doesn't include it; they don't replace the conversation about what to do with the result. See our guide to at-home blood tests for women for a fuller comparison.